Shilpa Medicare intends to enlarge its Onco Block by financial year 2027, focusing on introducing novel cancer treatments. The expansion is designed to support the company's growth in the oncology sector.

Shilpa Medicare significantly boosted its Q4 net profit by approximately 700% year-on-year, reaching ₹108 crore, with revenue increasing 32% to ₹437 crore. Additionally, EBITDA rose 49.6% and maintained a margin of 27.4%.

Shilpa Medicare has finalized its FY25-26 financial reports, receiving an unqualified assessment from the auditor. Shareholders are set to receive a dividend of ₹0.60 per share. The company also appointed new auditors and acquired a 28% stake in a renewable energy firm.

Shilpa Medicare secures approval from the CDSCO for its albumin Phase 3 trial, a significant step forward. The company plans to submit an application to the European Medicines Agency (EMA) during the first half of fiscal year 2027.

Shilpa Medicare has finished developing its laboratory for the production of teduglutide, with process validation trials scheduled for the first half of their fiscal year 2027.

Shilpa Medicare has demonstrated a remarkable financial turnaround, reporting a 108% increase in Q4 profit to ₹954 million compared to last year. This noteworthy progress signals a promising trajectory for the company's financial health.

Shilpa Medicare has surpassed its resistance level, suggesting a potential bullish phase with increasing optimism among investors. The upward trend is reinforced by growing volume and consistent highs and lows.

Shilpa Medicare is set to discuss its Q4 and full-year FY26 audited financial results, along with the dividend recommendation for the fiscal year FY25-26, during their board meeting on May 22, 2026. The trading window has been closed since April 1, 2026.

Shilpa Medicare is currently demonstrating positive momentum, with strong technical indicators such as the 21 Day Moving Average (DMA) at 420 and a crossover of the 55 DMA and 200 DMA. This resilience during market downturns, coupled with solid fundamentals, makes it an attractive investment prospect.

Foreign institutional investors (FIIs) have shown increased interest in the Indian pharmaceutical sector, as evidenced by their growth in stakes for companies like Shilpa Medicare, Marksans Pharma, and Jagsonpal Pharma during Q1 FY26. Notably, Shilpa Medicare is expanding its presence in Latin America, Marksans Pharma has secured FDA approvals, while Jagsonpal Pharma focuses on women's health and maintaining financial discipline.

Axis Securities suggests investors consider Voltamp Transformers, Shilpa Medicare, and Persistent Systems as potential buys. Despite crude price worries, both Nifty 50 and Sensex experienced slight growth on April 2, with Nifty rising by 0.15% to 22,713.1 and Sensex increasing by 0.25% to 73,319.55.